---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-032290"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:39:42.682045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement

## Summary
- Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.
- Gross margin improved to 53.5% from 53.3% on supply chain cost savings.
- Net loss narrowed to $2.1M ($0.10/share) from $3.4M ($0.24/share) YoY.
- Received CMS reimbursement for Ekso Indego Personal, enabling Medicare coverage for SCI patients.
- Cash $8.3M at Sep 30, 2024; raised $5.0M net in underwritten offering during September.

## SEC filing metadata
- accession: 0001437749-24-032290
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774924032290/0001437749-24-032290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774924032290/ekso20241018_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-032290
- JSON: https://secwatch.observer/filing/0001437749-24-032290.json
- Plain text: https://secwatch.observer/filing/0001437749-24-032290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.